Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06541652

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hepatocholangiocarcinoma Adenocarcinoma Carcinoma Cholangiocarcinoma Digestive System Diseases Digestive System Neoplasms Fibrolamellar Carcinoma Fibrolamellar hepatocellular carcinoma Hepatic Angiosarcomas Hepatic Carcinosarcomas Hepatic Cystadenoma Hepatic Epithelioid Hemangioendothelioma Hepatic Leiomyosarcomas Hepatic Neuroendocrine Carcinoma Hepatoblastoma Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Complex and Mixed Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens picardie, Amiens, France

Loading trial locations.

About this study

The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older,
  • with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
  • diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
  • for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.

Exclusion criteria

  • without social security
  • No access to tumor block

Treatment and study plan

Primary outcomes

  1. Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

    Time frame: up to 5 years from the date of diagnosis

    Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

Secondary outcomes

  1. Recurrence-free survival (for non-metastatic patients)

    Time frame: up to 5 years from diagnosis

    Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news

  2. Progression-free survival (for metastatic patients)

    Time frame: up to 5 years from diagnosis

    Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news.

  3. Overall survival

    Time frame: up to 5 years from diagnosis

    Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news.

Study contacts

Contact information is provided by the study sponsor or research team.

lila gaba

CONTACT

[email protected]

06 99 78 84 73

Sponsors and collaborators

Lead sponsor

Federation Francophone de Cancerologie Digestive

Other

Collaborators

  • Société Nationale Française de Gastroentérologie

Registry information

Acronym: FFCD-2205

Important dates

Study start
2024
Primary completion
2026
Study completion
2031
First posted
Aug 7, 2024
Registry last updated
Aug 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.